Review Articles
Epidemic of COVID-Associated Mucormycosis in India and a road ahead
Authors:
S. Sharma ,
Ramkrishna Care Medical Sciences Pvt. Ltd., Raipur, IN
About S.
Department of Neurology
P. Sharma,
Ramkrishna Care Medical Sciences Pvt. Ltd., Raipur, IN
About P.
Department of Neurology
U. K. Chandra,
Ramkrishna Care Medical Sciences Pvt. Ltd., Raipur, IN
About U. K.
Department of Neurology
S. Javed,
Ramkrishna Care Medical Sciences Pvt. Ltd., Raipur, IN
About S.
Department of Neurology
A. Nambiar,
VPS Lakeshore Hospital , Kochi, Kerala, IN
About A.
Department of Internal Medicine
V. K. Sharma
National University Health System, SG
About V. K.
Division of Neurology, University Medicine Cluster
Abstract
COVID-associated Mucormycosis (CAM) was a peak-hour crisis in India. The situation arose from an unprecedented ICU workload of critical COVID-19 cases, insufficient resources and the impaired immune status of the patient. We recommend strong preventive measures, chemoprophylaxis and Amphotericin-B nebulisation for the effective management of CAM.
How to Cite:
Sharma S, Sharma P, Chandra UK, Javed S, Nambiar A, Sharma VK. Epidemic of COVID-Associated Mucormycosis in India and a road ahead. Asian Journal of Internal Medicine. 2023;2(1):38–42. DOI: http://doi.org/10.4038/ajim.v2i1.71
Published on
07 Feb 2023.
Peer Reviewed
Downloads
